Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KYMR Kymera Therapeutics, Inc.

Not Yet Opened 04-23 16:00:00 EDT

30.70

+1.90

+6.60%

盘后30.70

+0.000.00%

16:20 EDT

High31.07	Low29.54	Vol1.02M
Open29.54	D1 Closing28.80	Amplitude5.31%
Mkt Cap1.99B	Tradable Cap1.31B	Total Shares64.94M
T/O31.17M	T/O Rate2.37%	Tradable Shares42.82M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"KYMR","market":"US","secType":"STK","nameCN":"Kymera Therapeutics, Inc.","latestPrice":30.7,"timestamp":1745438400000,"preClose":28.8,"halted":0,"volume":1015387,"hourTrading":{"tag":"盘后","latestPrice":30.7,"preClose":30.7,"latestTime":"16:20 EDT","volume":20214,"amount":620583.825,"timestamp":1745439600599},"delay":0,"floatShares":42816084,"shares":64944136,"eps":-2.983023,"marketStatus":"Not Yet Opened","change":1.9,"latestTime":"04-23 16:00:00 EDT","open":29.54,"high":31.07,"low":29.54,"amount":31172359.2491,"amplitude":0.053125,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.983023,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745481600000},"marketStatusCode":0,"adr":0,"listingDate":1597982400000,"exchange":"NASDAQ","adjPreClose":28.8,"preHourTrading":{"tag":"盘前","latestPrice":30.19,"preClose":28.8,"latestTime":"09:29 EDT","volume":500,"amount":15062.67,"timestamp":1745414999999},"postHourTrading":{"tag":"盘后","latestPrice":30.7,"preClose":30.7,"latestTime":"16:20 EDT","volume":20214,"amount":620583.825,"timestamp":1745439600599},"volumeRatio":1.767071,"impliedVol":0.5862,"impliedVolPercentile":0.26},"requestUrl":"/m/hq/s/KYMR/wiki","defaultTab":"wiki","newsList":[{"id":"2529437121","title":"Kymera Therapeutics Inc - KT-621 Phase 1 Healthy Volunteer Trial Data Expected in June 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2529437121","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529437121?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 19:00","pubTimestamp":1745319601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7JLNM5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2529371141","title":"Kymera Therapeutics Announces First Patient Dosed in Broaden Phase 1B Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral Stat6 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2529371141","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529371141?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 19:00","pubTimestamp":1745319601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7JLNM5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["KYMR","BK4139"],"gpt_icon":0},{"id":"2529249371","title":"Kymera Therapeutics Inc - Phase 2B Trials in Ad and Asthma to Start in 4Q25 and 1Q26","url":"https://stock-news.laohu8.com/highlight/detail?id=2529249371","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529249371?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 19:00","pubTimestamp":1745319601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250422:nTUA7JLNM5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","KYMR"],"gpt_icon":0},{"id":"2529372760","title":"Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2529372760","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529372760?lang=en_us&edition=full_marsco","pubTime":"2025-04-22 19:00","pubTimestamp":1745319600,"startTime":"0","endTime":"0","summary":"Data from the BroADen Phase 1b atopic dermatitis  patient trial expected to be reported in 4Q25. Completed SAD/MAD dosing in KT-621 Phase 1 healthy volunteer trial with data to be reported in June 2025. Two parallel Phase 2b trials in AD and asthma planned to start in 4Q25 and 1Q26, respectively. Two parallel Phase 2b clinical trials in moderate to severe AD and asthma patients are expected to begin in the fourth quarter of 2025 and the first quarter of 2026, respectively. These studies are intended to accelerate KT-621 development and enable dose selection for subsequent parallel Phase 3 registration studies across multiple Th2 dermatology, gastroenterology and respiratory indications.About KT-621KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Th2 inflammation. STAT6 degradation has the potential to","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-announces-first-patient-110000055.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4096","LENZ","LU0541501648.USD","BK4115","KYMR","PN","KT","LU0541502299.USD","EASI","BK4007","BK4139"],"gpt_icon":0},{"id":"2526516775","title":"Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526516775","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526516775?lang=en_us&edition=full_marsco","pubTime":"2025-04-10 22:10","pubTimestamp":1744294200,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc.  shares ended the last trading session 13.8% higher at $23.95. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 36.7% loss over the past four weeks.Shares rallied due to broader market optimism following President Trump's tweet that there would be a 90-day pause on reciprocal tariffs for non-retaliating countries. Kymera also announced the appointment of Noah Goodman as its new Chief Business Officer.For Kymera Therapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on KYMR going forward to see if this recent jump can turn into more strength down the road.Kymera Therapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymera-therapeutics-kymr-moves-13-141000475.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["KYMR","BHST","BK4139","BK4183"],"gpt_icon":0},{"id":"2526573503","title":"Kymera Therapeutics appoints Goodman as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526573503","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526573503?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:10","pubTimestamp":1744197055,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Goodman brings a wealth of diverse experie...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-appoints-goodman-as-chief-business-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kymera-therapeutics-appoints-goodman-as-chief-business-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","LENZ","KYMR"],"gpt_icon":0},{"id":"2526354646","title":"Press Release: Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2526354646","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526354646?lang=en_us&edition=full_marsco","pubTime":"2025-04-09 19:00","pubTimestamp":1744196400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., April 09, 2025  -- Kymera Therapeutics, Inc. , a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development strategy and activities for the company.Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation  to develop medicines that address critical health problems and have the potential to dramatically improve patients' lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, hi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","KYMR","BK4585","BK4135","BK4588","BK4531","NOAH","BK4007","LENZ"],"gpt_icon":0},{"id":"2520195421","title":"Top Analyst Reports for Shell, Uber & TotalEnergies","url":"https://stock-news.laohu8.com/highlight/detail?id=2520195421","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520195421?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 06:31","pubTimestamp":1742423460,"startTime":"0","endTime":"0","summary":"Wednesday, March 19, 2025The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Shell plc (S","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/top-analyst-reports-shell-uber-223100107.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4017","BK4117","IE00B19Z3581.USD","GEOS","LU2129689605.HKD","PEG","LU2491049909.HKD","PRM","TTE","SG9999014898.SGD","BK4084","EVR","KYMR","LU0444973449.USD","LU0654597011.USD","BK4503","IE00BMG7P694.USD","FMS","SHEL","UBER","IE00BMG7P819.SGD","LU0353189680.USD","WPM","BK4183","CCI","LU0266013472.USD","BK4504","DECK","LU2517655028.SGD","BK4528","LU2264538146.SGD","ATGE","DD","GDDY","LU0353189763.USD","IRDM","AFG","NHTC","LU2210150020.SGD","SG9999017495.SGD","BK4566","BK4230","BK4107","BK4567","LU1162221912.USD","LU0320765646.SGD","LU2210149790.SGD","LU0098860793.USD","RARE","BK4196"],"gpt_icon":0},{"id":"2519856750","title":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTx","url":"https://stock-news.laohu8.com/highlight/detail?id=2519856750","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519856750?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 23:47","pubTimestamp":1741880850,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Metropolitan Bank, Fossil, MeiraGTxEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW19Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GIII","MGTX","ETNB","IE00BMPRXQ63.HKD","BK4570","BBW","LU1496350171.SGD","LU2498475776.HKD","MNTK","AEYE","LU2250418816.HKD","LU2430703178.SGD","NOVA","LYV","KNSA","TRIB","LU2065169927.USD","LU2506952170.USD","ATEN","PCAR","TARS","FOSL","LU1043141123.HKD","ALKT","LU2317271919.USD","NN","AVAH","KYMR","LU0276348264.USD","SPIR","APGE","AEO","NVAX","LU0238689110.USD","DLTR","MCB","NEM","LU0162691827.USD","LU0096364046.USD","IE00BJJMRX11.SGD"],"gpt_icon":1},{"id":"2519393418","title":"BUZZ-Citigroup starts coverage of Kymera with $52 PT","url":"https://stock-news.laohu8.com/highlight/detail?id=2519393418","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519393418?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 20:40","pubTimestamp":1741869647,"startTime":"0","endTime":"0","summary":"BUZZ-Citigroup starts coverage of Kymera with $52 PT** Citigroup starts coverage of Kymera Therapeutics' KYMR.O shares with \"buy/high risk\" rating and $52 PT, a ~48% upside to stock's last close** Brokerage says company's targeted protein degradation technology offers \"first-in-class\" approaches in the treatment of various inflammatory and immunological diseases** Company's atopic dermatitis drug KT-621 has shown \"robust preclinical data\" with potential to achieve \"comparable or superior efficacy\" to Regeneron REGN.O and Sanofi's SASY.PA  Dupixent, Citigroup says** Kymera's inflammatory skin disease drug KT-474 has shown promising data in clinical trials, particularly in hidradenitis suppurativa, where it demonstrated a \"remarkable ~60% reduction in symptoms\", positioning it as a potential \"best-in-class\" therapy - brokerage** Brokerage estimates company's revenue to reach $1 bln by 2032, with each additional $500 bln in sales potentially adding $20 to the stock price** Kymera's shares","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0YV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2023250504.SGD","KYMR","LU0889565916.HKD","LU0058720904.USD","BK4588","LU1917777945.USD","LU1974910355.USD","LU0823416689.USD","LU0289739699.SGD","LU2362541273.HKD","LU2237438978.USD","LU0109394709.USD","LU0114720955.EUR","REGN","LU2089984988.USD","BK4585","LU2362541513.USD","LU2106854487.HKD","LU2362540622.SGD","LU2468319806.SGD","LU0320765992.SGD","BK4139","LU0053666078.USD","LU0882574055.USD"],"gpt_icon":0},{"id":"2519880301","title":"Citigroup Initiates Coverage on Kymera Therapeutics With Buy Rating, $52 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2519880301","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519880301?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 19:13","pubTimestamp":1741864412,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR) has an average rating of Buy and mean price target of $58.82, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","KYMR"],"gpt_icon":0},{"id":"2519878538","title":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty","url":"https://stock-news.laohu8.com/highlight/detail?id=2519878538","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519878538?lang=en_us&edition=full_marsco","pubTime":"2025-03-13 18:56","pubTimestamp":1741863404,"startTime":"0","endTime":"0","summary":"BUZZ-Citi starts coverage on 'insulated' SMid biotechs amid healthcare policy uncertainty   ** Brokerage Citi initiates coverage on eight small and mid-cap  biotechs - 89bio ETNB.O, Apogee Therapeutics APGE.O, Avidity Biosciences RNA.O, BioNTech 22UAy.DE, Kiniksa Pharmaceuticals KNSA.O, Kymera Therapeutics KYMR.O, Moderna MRNA.O and PTC Therapeutics PTCT.O** Citi suggests SMid biotechs could be a good alternative to larger-cap stocks amid healthcare policy uncertainty** Recent economic uncertainties, including increased tariffs and slowing economic growth, have \"underscored the defensive attributes\" of biotech and pharma stocks, brokerage says ** Higher-growth large caps such as Eli Lilly LLY.N and Vertex Pharma VRTX.O are likely able to absorb potential policy headwinds and \"catalyst-driven\" SMid biotechs are \"insulated from macro uncertainties\" - Citi** YTD, S&P500 Health Care index .SPXHC has grown ~5%, NYSE Arca Pharmaceutical Index .DRG has gained ~6% and NASDAQ Biotechnology Inde","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nL4N3PW0SW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0109391861.USD","IE00BFTCPJ56.SGD","SG9999018865.SGD","LU0106261372.USD","PTCT","KNSA","IE00B19Z3B42.SGD","LU0061475181.USD","BK4139","ETNB","LU1989771016.USD","LU2265009873.SGD","LU1868836591.USD","LU1093756325.SGD","LU2237443978.SGD","LU0238689110.USD","APGE","LU1280957306.USD","RNA","LU2063271972.USD","LU0006306889.USD","LU1720051017.SGD","LU1291159041.SGD","LU1868837136.USD","VRTX","SGXZ81514606.USD","IE0002141913.USD","KYMR","LU1551013342.USD","BK4533","LU2211815571.USD","IE00B894F039.SGD","LU0096364046.USD","LU0320765059.SGD","LU2023250504.SGD","LU2237443465.HKD","LU0417517546.SGD","LU2362541513.USD","LU1868837300.USD","SG9999014898.SGD","BK4007","LU0097036916.USD","LU2089984988.USD","SG9999017495.SGD","LU0820561909.HKD","MRNA","LU1917777945.USD","IE00BJLML261.HKD","LU1064131342.USD"],"gpt_icon":1},{"id":"2517436994","title":"Analysts Offer Insights on Healthcare Companies: Myomo (MYO), Kymera Therapeutics (KYMR) and Anika Therapeutics (ANIK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2517436994","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517436994?lang=en_us&edition=full_marsco","pubTime":"2025-03-07 22:10","pubTimestamp":1741356626,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Myomo (MYO – Research Report), Kymera Therapeutics (...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-myomo-myo-kymera-therapeutics-kymr-and-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-myomo-myo-kymera-therapeutics-kymr-and-anika-therapeutics-anik?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ANIK","BK4139","MYO","HCSG","BK4137","KYMR","BK4082"],"gpt_icon":0},{"id":"2516645916","title":"Kymera Therapeutics Grants Performance Stock Units to Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2516645916","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516645916?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 06:03","pubTimestamp":1741039396,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics ( ($KYMR) ) has shared an update. On March 3, 2025, Kymera Therapeutics’ Board and Compensation Committee approved the grant of...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-grants-performance-stock-units-to-executives?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-grants-performance-stock-units-to-executives?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","KYMR","BK4139"],"gpt_icon":0},{"id":"2516586714","title":"Kymera Therapeutics’ Earnings Call Highlights Progress and Challenges","url":"https://stock-news.laohu8.com/highlight/detail?id=2516586714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516586714?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 08:29","pubTimestamp":1740788993,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. (($KYMR)) has held its Q4 earnings call. Read on for the main highlights of the call. Kymera Therapeutics’ recent earning...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kymera-therapeutics-earnings-call-highlights-progress-and-challenges?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PRGS","KYMR","LENZ"],"gpt_icon":0},{"id":"2516130552","title":"Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2516130552","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516130552?lang=en_us&edition=full_marsco","pubTime":"2025-03-01 02:12","pubTimestamp":1740766320,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics, Inc. KYMR reported a fourth-quarter 2024 loss of 88 cents per share, wider than the Zacks Consensus Estimate of a loss of 76 cents. In the year-ago quarter, Kymera reported a loss of 25 cents per share.The year-over-year deterioration was due to lower collaboration revenues and higher operating expenses.Collaboration revenues totaled $7.4 million, which missed the Zacks Consensus Estimate of $13 million.In the year-ago quarter, Kymera earned collaboration revenues of $47.9 million due to the recognition of milestone payments related to the advancement of KT-474 into phase II testing under its collaboration with pharma bigwig Sanofi SNY.Shares of KYMR have lost 30.1% year to date compared with the industry’s decline of 8%.In October, Kymera initiated the phase I study on KT-621 in healthy volunteers. KT-621 is an investigational, first-in-class, once daily, oral degrader of STAT6.Kymera intends to advance KT-295, an investigational, first-in-class, once daily, oral ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kymeras-q4-loss-wider-expected-181200761.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["GILD","LU2089984988.USD","BK4568","BK4139","LU1571399168.USD","LU2468319806.SGD","IE00BFXG1179.USD","IE00B19Z3581.USD","LU0058720904.USD","LU1839511570.USD","LU0109394709.USD","LU2087621335.USD","LU0289739699.SGD","BK4007","IE00BZ1G4Q59.USD","KYMR","IE00BKVL7J92.USD","IE00BSNM7G36.USD","IE00B19Z3B42.SGD","SNY","BK4566","IE00B7SZLL34.SGD","LU0889565916.HKD","LU1430594728.SGD","BK4588","BK4585","IE0002270589.USD","LU0320765992.SGD","LU0234570918.USD","BMRN","IE00B3T34201.USD","LU1066053197.SGD","LU1066051498.USD","LU1585245621.USD","BK4583","BK4532","BK4550","BK4578"],"gpt_icon":0},{"id":"2514214303","title":"Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (LMAT), Dyne Therapeutics (DYN) and Kymera Therapeutics (KYMR)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514214303","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514214303?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 21:20","pubTimestamp":1740748816,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Lemaitre Vascular (LMAT – Research Report), Dyne Therapeutics (DY...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lemaitre-vascular-lmat-dyne-therapeutics-dyn-and-kymera-therapeutics-kymr?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-lemaitre-vascular-lmat-dyne-therapeutics-dyn-and-kymera-therapeutics-kymr?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4082","BK4137","BK4505","HCSG","LMAT","BK4139","BK4585","DYN","BK4588","KYMR"],"gpt_icon":0},{"id":"2514432866","title":"Kymera Therapeutics: Buy Rating Affirmed Amid Promising STAT6 Program Developments and Adjusted Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2514432866","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514432866?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:40","pubTimestamp":1740742819,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Andrew Fein has maintained their bullish stance on KYMR stock, giving a Buy rating yesterday. Andrew Fein has given his Buy...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-buy-rating-affirmed-amid-promising-stat6-program-developments-and-adjusted-price-target?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-buy-rating-affirmed-amid-promising-stat6-program-developments-and-adjusted-price-target?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","KYMR"],"gpt_icon":0},{"id":"2514642323","title":"We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2514642323","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514642323?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 19:36","pubTimestamp":1740742599,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made losses for many years after listing, if you had bought and held the shares since 1999, you would have made a fortune. But while history lauds those rare successes, those that fail are often forgotten; who remembers Pets.com?So, the natural question for Kymera Therapeutics  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. First, we'll determine its cash runway by comparing its cash burn with its cash reserves.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/were-not-very-worried-kymera-113639468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2095319765.USD","USJW.SI","BK4139","TSYW.SI","LU2210150020.SGD","NVIW.SI","IE00BGHQF748.EUR","USAW.SI","SQQQ","NDAQ","QID","BK4112","BK4585","IE00B3QW5Z07.USD","TQQQ","IE00B64PRP62.GBP","QLD","MNQmain","LU2210149790.SGD","NQmain","KYMR","IE00BKPKM429.USD","PSQ","BK4588",".IXIC"],"gpt_icon":1},{"id":"2514349969","title":"Kymera Therapeutics: Promising Developments and Strategic Positioning Make It a Compelling Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2514349969","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514349969?lang=en_us&edition=full_marsco","pubTime":"2025-02-28 17:57","pubTimestamp":1740736673,"startTime":"0","endTime":"0","summary":"Kymera Therapeutics (KYMR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Derek Archil...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-promising-developments-and-strategic-positioning-make-it-a-compelling-buy?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/kymera-therapeutics-promising-developments-and-strategic-positioning-make-it-a-compelling-buy?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","KYMR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kymeratx.com","stockEarnings":[{"period":"1week","weight":0.227},{"period":"1month","weight":-0.089},{"period":"3month","weight":-0.3059},{"period":"6month","weight":-0.3603},{"period":"1year","weight":-0.1403},{"period":"ytd","weight":-0.2369}],"compareEarnings":[{"period":"1week","weight":0.0186},{"period":"1month","weight":-0.0673},{"period":"3month","weight":-0.1219},{"period":"6month","weight":-0.0753},{"period":"1year","weight":0.0589},{"period":"ytd","weight":-0.0864}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.085982},{"month":2,"riseRate":0.2,"avgChangeRate":-0.068972},{"month":3,"riseRate":0.2,"avgChangeRate":-0.073393},{"month":4,"riseRate":0.6,"avgChangeRate":-0.012923},{"month":5,"riseRate":0.25,"avgChangeRate":-0.150138},{"month":6,"riseRate":0.5,"avgChangeRate":0.024718},{"month":7,"riseRate":0.75,"avgChangeRate":0.214781},{"month":8,"riseRate":0.75,"avgChangeRate":0.05865},{"month":9,"riseRate":0.2,"avgChangeRate":-0.112915},{"month":10,"riseRate":0.6,"avgChangeRate":0.065},{"month":11,"riseRate":0.6,"avgChangeRate":0.197535},{"month":12,"riseRate":0.6,"avgChangeRate":0.083852}],"exchange":"NASDAQ","name":"Kymera Therapeutics, Inc.","nameEN":"Kymera Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kymera Therapeutics, Inc.,KYMR,Kymera Therapeutics, Inc.股票,Kymera Therapeutics, Inc.股票老虎,Kymera Therapeutics, Inc.股票老虎国际,Kymera Therapeutics, Inc.行情,Kymera Therapeutics, Inc.股票行情,Kymera Therapeutics, Inc.股价,Kymera Therapeutics, Inc.股市,Kymera Therapeutics, Inc.股票价格,Kymera Therapeutics, Inc.股票交易,Kymera Therapeutics, Inc.股票购买,Kymera Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kymera Therapeutics, Inc.(KYMR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kymera Therapeutics, Inc.(KYMR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}